TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook

TD Cowen downgraded Novo Nordisk to Hold from Buy and cut the price target to $42 from $45 (now implying ~6% upside). Shares have fallen 22% YTD and about 50% over the past 12 months. The analyst cited mounting branded competition, looming semaglutide patent expirations (patent secured through 2032 but lapsing in some countries this month), and underwhelming CagriSema trial results as key headwinds to the company’s post-semaglutide trajectory.

Analysis

Market moves are pricing in a structural downgrade to the lead GLP-1 incumbent rather than a temporary earnings miss; the more important channel is psychology — once investor focus shifts from growth to durability of exclusivity, valuation multiples compress far faster than revenue erosion. Expect a front-loaded rerating over 3–12 months driven by margin reversion (gross-to-net expansion), increased marketing spend to defend share, and earlier-than-anticipated branded entrants winning formulary placement.

Second-order winners include large rivals with late-stage dual-agon programs and diversified franchises that can reallocate commercial muscle into obesity/diabetes quickly; device and single-use injector suppliers face a multi-year demand shift risk if oral GLP-1s scale, while contract manufacturers for biologics may see choppy volumes and pricing pressure. PBMs and large insurers will likely exert more leverage into pricing as a broader cash-pay market emerges, tightening payor economics over 12–36 months and compressing net prices for incumbents.

Key catalysts to watch on separate timelines: near-term (weeks–months) — regulatory approvals, patent-litigation headlines, and enrollment signals from branded challengers; medium-term (6–24 months) — branded competitor launches and formulary wins that materially change net realized price; long-term (2–5 years) — generic/biologic entrants and any successful next-gen molecule readouts that could restore investor confidence. A reversal is plausible if the incumbent posts convincing clinical differentiation or a credible lifecycle-management roadmap that stabilizes net price and market share within 6–12 months.

Key Decisions for Investors

• Pair trade (6–18 months): Short NVO notional vs long LLY (1:1 notional). Rationale: hedge direct GLP-1/obesity exposure while capturing share-shift to a diversified competitor; use size such that P/L sensitivity to a 20% move in NVO is matched by ~10–15% move in LLY. Risk: downside if market re-rates incumbents higher on defense messaging; consider using puts on NVO to cap drawdown.
• Options hedge (3–9 months): Buy NVO 6‑month put spread to limit premium paid (buy deep OTM put, sell lower strike put). Target strikes ~10–25% below current levels depending on premium; this offers asymmetric payoff if branded competition accelerates. Risk: time decay and potential early bounce on positive pipeline news.
• Long competitors (12–24 months): Accumulate LLY and AZN on weakness — allocate tactical overweight with a 12–24 month horizon as they capture incremental share and benefit from diversified revenue streams. Reward: durable rerating if they convert weight-loss share; risk: class-wide pricing pressure and regulatory setbacks.
• Supply-chain play (12+ months): Underweight contract biologics manufacturers and single-use device names (e.g., WST) while screening specialty pharma CDMOs with oral formulation expertise. Mechanism: demand reallocation from injectable biologics to oral small-molecule/peptide formats; risk: incumbent retains injectable dominance longer-than-expected.